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Introduction and Aims. The first COVID-19 case in Malta was confirmed on the 7th of March 2020. This study is aimed at
investigating a significant difference between the number of acute exacerbations of chronic obstructive pulmonary disease
(AECOPD) admissions and their inpatient outcome at Mater Dei Hospital during the COVID-19 pandemic when compared to
the same period in 2019. Furthermore, we aim to determine predictors of mortality in AECOPD inpatients. Method. Data was
collected retrospectively from electronic hospital records during the periods 1st March until 10th May in 2019 and 2020. Results.
There was a marked decrease in AECOPD admissions in 2020, with a 54.2% drop in admissions (n = 119 in 2020 vs. n = 259 in
2019). There was no significant difference in patient demographics or medical comorbidities. In 2020, there was a significantly
lower number of patients with AECOPD who received nebulised medications during admission (60.4% in 2020 vs. 84.9% in
2019; p ≤ 0:001). There were also significantly lower numbers of AECOPD patients admitted in 2020 who received controlled
oxygen via venturi masks (69.0% in 2020 vs. 84.5% in 2019; p = 0:006). There was a significant increase in inpatient mortality in
2020 (19.3% [n = 23] and 8.4% [n = 22] for 2020 and 2019, respectively, p = 0:003). Year was found to be the best predictor of
mortality outcome (p = 0:001). The lack of use of SABA pre-admission treatment (p = 0:002), active malignancy (p = 0:003), and
increased length of hospital stay (p = 0:046) were also found to be predictors of mortality for AECOPD patients; however, these
parameters were unchanged between 2019 and 2020 and therefore could not account for the increase in mortality. Conclusions.
There was a decrease in the number of admissions with AECOPD in 2020 during the COVID-19 pandemic, when compared to
2019. The year 2020 proved to be a significant predictor for inpatient mortality, with a significant increase in mortality in 2020.
The decrease in nebuliser and controlled oxygen treatment noted in the study period did not prove to be a significant predictor
of mortality when corrected for other variables. Therefore, the difference in mortality cannot be explained with certainty in this
retrospective cohort study.
1. Introduction
The World Health Organization (WHO) declared COVID-
19 as a worldwide pandemic on the 11th of March 2020.
Since the first case detected in Wuhan, Hubei Province of
China on 31st December 2019, there have been 150.99 mil-
lion confirmed cases and 3.17 million deaths registered
worldwide as of 1st May 2021 [1]. As a result, people’s lives
have been impacted dramatically, economic growth grinding
to a halt, sending the world into a deep recession [2]. The
pandemic has also generated a challenge in the routine care
of hospitalised patients. Hospital administrations underwent
an overhaul with respect to patient management and treat-
ment protocols, aiming to limit the spread of COVID-19
among patients and healthcare workers.
COVID-19 is propagated by the spread of droplets, par-
ticularly by aerosol-generating procedures (AGPs) [3]. A
conflict of opinion arose among guidelines, where some
favoured the use of nebulisers as it was felt that this treatment
should not be classified as an AGP, while others recom-
mended abstaining from nebuliser use. In this context,
chronic obstructive pulmonary disease (COPD) patients
must be considered as they frequently suffer from acute exac-
erbations requiring hospital admission for treatment
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including nebulised bronchodilators. Therefore, patients
admitted with an acute exacerbation of COPD (AECOPD)
are at risk of being unable to access necessary treatment
due to a change in guidelines which could have adverse
effects on clinical outcomes [4].
During the pandemic, the first COVID-19 case in Malta
was confirmed on the 7th of March 2020, imported from Italy
[5]. The first cases of local transmission in Malta were later
recorded on the 16th of March 2020. As the COVID-19 pan-
demic began to affect the Maltese Islands, local guidelines
were implemented for inpatients judged to have a high risk
of carrying the virus. Until these patients were confirmed to
test negative for the SARS-CoV-2 virus, the use of nebulised
medications, venturi masks, and non-invasive ventilation
(NIV) was limited given the risk of aerosol production.
Therefore, this led to the alteration of local treatment guide-
lines for patients who presented with a deterioration in their
pre-existing respiratory condition, primarily asthma and
COPD, who are the main subgroup of patients who use these
treatment modalities.
During the H1N1 pandemic, a study about social behav-
iour found that even in the early stages of the pandemic, peo-
ple in Hong Kong started to avoid going to hospital due to a
fear of contracting the virus. This fear stemmed from previ-
ous experience during the SARS pandemic [6]. In March of
2020, during the first wave of COVID-19, this phenomenon
was also demonstrated inMalta, where there was a significant
decline in patients presenting with acute cardiac conditions
such as myocardial infarctions. A delay in presentation to
the Emergency Department (ED) was demonstrated due to
a fear of contracting COVID-19 from within the hospital
[7]. Containment measures have also impacted hospitaliza-
tion rates of strokes [8] and myocardial infarctions [9] in
centres abroad. A single-centre study in Germany noted a
decrease in AECOPD admissions, and the authors postulated
that the reasons were multifactorial. The factors discussed
include possible COVID-19 protection with COPD treat-
ment, improvement in air quality secondary to lockdown
measures, and reduced face-to-face interaction, altogether
contributing towards a reduction in AECOPD admissions
[10]. Leung et al. (2020) also noted that data for patients pre-
senting with an AECOPD during this pandemic may be
skewed because such patients abstain from presenting to hos-
pital due to fear of exposure to SARS-CoV-2, or may seek
help late in the disease course, resulting in delayed manage-
ment and excess mortality in this subgroup [11]. We
hypothesised that the decline and delay in presentation of
AECOPD admissions noted in other centres was mirrored
locally.
2. Aim
The aim of this study was to establish the impact of COVID-
19 pandemic on the number of AECOPD hospital admis-
sions and their inpatient outcome at Mater Dei Hospital,
Malta, between 1st March and 10th May 2020, by comparing
to the corresponding period in 2019. Furthermore, we aimed
to determine predictors of mortality in AECOPD inpatients.
3. Method
This study was a retrospective, observational, cross-sectional
study. Data was collected from electronic hospital records.
No patients were approached or contacted at any point for
the study, and no unique identifying information was col-
lected. The study protocol was approved by the local ethics
committee (University of Malta, reference number:
FRECMDS_1920_182).
All patients over the age of 18, admitted to Mater Dei
Hospital with AECOPD between the 1st of March and 10th
of May 2020, were included in this study. The same period
from 2019 was used as a control. The diagnosis of an
AECOPD was based on the following criteria: change in sta-
ble symptoms including increased exertional dyspnoea,
chronic cough, and wheeze; the patient’s own past medical
history and social history, with particular attention to smok-
ing history; imaging; and a response to inhalers and nebu-
lised medications. There were no exclusion criteria. Patients
were considered negative for COVID-19 based on results
using reverse transcription polymerase chain reaction (RT-
PCR).
Assuming a population of 20,000 (4% prevalence of the
Maltese population as based on the European Health Inter-
view Survey 2014) and a confidence level of 95%, a sample
size of 377 was needed. Statistical analyses were performed
using IBM SPSS (SPSS Inc., USA). Variables included gender,
locality, medical comorbidities, management modalities
used, and inpatient treatment. All variables between the
groups were compared using chi-square analysis, Kruskal-
Wallis test, and Spearman 2-tailed correlations, accepting a
p value ≤0.05 as significant. The Fisher exact test was used
in cases where sample size was small, such as in the case of
non-invasive ventilation use, intensive care admission, and
tracheal intubation rate.
To determine predictors of mortality in both cohorts of
AECOPD inpatient admissions, a univariate analysis of mor-
tality was carried out using the chi-square test for categorical
datasets and independent samples t-test for continuous
variables.
The major limitation of the chi-square test and indepen-
dent samples t-test is that they investigate the relationship
between mortality outcome and a single predictor. It is well
known that a lone predictor could be rendered a very impor-
tant contributor in explaining variations in the mortality out-
come but would be rendered unimportant in the presence of
other predictors. In other words, the suitability of a predictor
in a model fit often depends on what other predictors are
included with it. To address this limitation, a logistic regres-
sion model was fitted to relate mortality outcome (dependent
variable) to the predictors of mortality described above. A
forward stepwise procedure was used to identify the parsimo-
nious model.
4. Results
A total of 119 and 260 patients were admitted with AECOPD
during the period of 1st March to 10th May 2020 and 2019,
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respectively, demonstrating a 54.2% drop in admissions.
There was no significant difference in the mean age of
patients (70.9 years in 2020, 71.7 years in 2019; p = 0:347).
The mean hospital length of stay for patients with AECOPD
was 6.76 days (5.89-7.6 days, 95% CI) and 6.74 days (5.48-
8.04 days, 95% CI) in 2020 and 2019, respectively
(p = 0:704). The mean number of previous hospital admis-
sions due to AECOPD per patient was 4.79 (3.48-6.11) and
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Figure 2: Number of active COVID-19 cases (total and per day) vs.
number of AECOPD admissions/day.
Table 1: Demographics and comorbidities of patients hospitalised with AECOPD and COPD pre-admission treatment.
Patient demographics
2019 2020 Chi-square p value
n % n %
Gender—male 199 76.5% 89 74.8%
0.137 0.711
Gender—female 61 23.5% 30 25.2%
Active smoker (within the last 6 months) 102 54.0% 38 43.7% 2.524 0.112
Comorbidity
Ischaemic heart disease 80 30.8% 28 23.5% 2.028 0.154
Chronic heart failure 103 39.6% 47 39.5% 0.000 0.986
Hypertension 159 61.1% 78 65.5% 0.879 0.349
Diabetes mellitus 71 27.3% 34 28.6% 0.057 0.812
Asthma 17 6.5% 5 4.2% 0.811 0.368
Cerebrovascular disease 22 8.4% 9 7.6% 0.086 0.770
Peripheral vascular disease 19 7.3% 5 4.2% 1.361 0.243
Pulmonary embolism/deep vein thrombosis 11 4.2% 3 2.5% 0.688 0.407
Active malignancy 27 10.4% 18 15.1% 1.771 0.183
Psychiatric history 44 16.9% 23 19.3% 0.257 0.612
COPD pre-admission treatment
SABA 179 71.0% 90 78.3% 2.108 0.146
LABA 136 54.0% 57 49.6% 0.614 0.433
SAMA 158 62.7% 77 67.0% 0.622 0.430
LAMA 32 12.7% 21 18.3% 1.977 0.160
ICS 122 48.4% 45 39.1% 2.744 0.098
Home nebulisers 21 8.3% 6 5.2% 1.167 0.280
Home NIV 6 2.4% 3 2.6% 0.014 0.906
Home LTOT 64 25.4% 29 25.0% 0.007 0.935
SABA: short-acting beta-agonist; LABA: long-acting beta-agonist; SAMA: short-acting muscarinic antagonist; LAMA: long-acting muscarinic antagonist; ICS:
inhaled corticosteroid use; NIV: non-invasive ventilation; LTOT: long-term oxygen therapy.
Year of admission


























Error bars: 95% CI
Figure 1: Graph showing the mean time between onsets of
symptoms prior to presentation in AECOPD hospitalisations in
2019 compared with 2020.
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4.05 (3.32-4.78) in 2020 and 2019, respectively (p = 0:148).
There were no significant differences between the two study
groups with respect to demographics, comorbidities, or
COPD pre-admission treatment (Table 1).
The mean time from onset of symptoms to hospital
admission was longer among patients admitted in 2020,
when compared to those admitted in 2019 (232.8 hours
(95% CI, 148.08-251.41) vs. 199.7 hours (95% CI, 83.53-
382.19)), although this difference did not reach statistical sig-
nificance (p = 0:076) (Figure 1).
A negative correlation was not noted between the num-
ber of active COVID-19 cases and AECOPD admissions to
hospital (correlation coefficient of -0.208, R = 0:03, with a p
value approaching statistical significance at 0.082) as illus-
trated in Figure 2.
None of the patients included in the study tested pos-
itive for the SARS-CoV-2 virus on RT-PCR testing; how-
ever, not all the patients were swabbed. Among the 2020
cohort, 83% (n = 99) of patients were screened for the
virus, 62% (n = 74) were swabbed once, 17% (n = 20) were
swabbed twice, and 4% (n = 5) were swabbed three times.
The number of swabs were related to hospital protocols
in place at the time which were largely based on the clin-
ical suspicion of COVID-19, the persistence of fever or
symptoms despite conventional treatment, or suspicious
findings on computed tomography. Patients were kept in
isolation until a negative swab was confirmed, as per hos-
pital protocol at the time.
There was a significant reduction in patients who were
administered nebulised treatment (salbutamol ±
ipratropium bromide) as an inpatient in 2020, when com-
pared to 2019 (60.4% [n = 58] vs. 84.9% [n = 191]; chi −
square = 23:162, p ≤ 0:001). In addition, a higher proportion
of AECOPD patients in 2020 received supplemental oxygen
therapy via a normal face mask or a non-rebreather mask
during their hospital stay (19% vs. 4.9%, chi − square =
12:024, p = 0:002) (Table 2).
No difference in escalation of care was noted between
2020 and 2019 (p = 0:457) (Table 3).
The proportion of inpatient deaths with an AECOPDwas
significantly higher in 2020 compared to 2019 (19.3% [n = 23
] vs. 8.5% [n = 22], respectively, chi-square 9.125; p = 0:003),
as demonstrated in Figure 3.
To determine predictors of mortality, 2020 and 2019
cohorts were both included in a logistic regression analysis.
When analysed individually using the chi-square test and the
independent samples t-test, four continuous variables and
nine categorical variables were found to be significantly related
to mortality outcome (Tables 4 and 5). Other predictors yield-
ing p values larger than the 0.05 criterion were excluded.
To correct for other predictors of mortality, a logistic
regression model was fitted to relate mortality outcome to
predictors described above (Table 6).
The logistic regression model identifies four significant
predictors. Year is the best predictor of mortality outcome
and is followed by the lack of use of SABA rescue treatment,
active malignancy, and increased length of stay. The Nagelk-
erke pseudo R-square value (0.654) indicates that this 4-
predictor parsimonious logistic regression model explains
65.4% of the total variation in the mortality outcome.
5. Discussion
In this study, we noted a significant decrease in the number
of admissions to Mater Dei Hospital in 2020, compared to
2019. Furthermore, an increased mortality was noted among
the 2020 cohort, where the year 2020 was found to be a signif-
icant predictor for inpatient mortality. A significant reduc-
tion in nebuliser and controlled oxygen use was noted,
although this did not significantly impact mortality.
The fall in the AECOPD hospital admission rate between
2019 and 2020 inMalta is likely multifactorial. It is difficult to
quantify any single contributing effect and may include
potentially improved air quality due to a reduction in air pol-
lution and particulate matter after the closure of businesses
and industry and reduced air, sea, and vehicular traffic,
increased use of facial masks with a potential resulting
decrease in other seasonal respiratory viruses, mandatory
shielding of people (including those with respiratory disease,
those over 65 years of age, and those on oral corticosteroids
and immunosuppressant medication), and fear of presenting
to health services due to risk of exposure to the SARS-CoV-2
virus. A similar trend was noted in a study conducted in
Hong Kong. Chan (2020) reported that during the first three
months of 2020, the admission rate for AECOPD decreased
by 44%, compared to the average admission rate in previous
years. In this study, the decrease was attributed to masking
and increased social distancing [12]. In contrast to Hong
Kong, during the period studied, mandatory mask wearing
Table 2: Oxygen treatment received in AECOPD inpatients during the study period.
2019, n (%) 2020, n (%) Chi-square p value
Venturi mask used (n) 120 (84.5%) 58 (69.0%) 7.541 0.006
Normal face mask/non-rebreather mask (n) 7 (4.9%) 16 (19.0%) 11.508 0.001
No oxygen mask (n) 15 (10.6%) 10 (11.9%) 0.097 0.756
Table 3: Escalation of care of patients hospitalised with AECOPD
(analysed using Fisher’s exact test).
Escalation of care 2019 2020 Fisher exact test Df p value
NIV (n) 24 9
1.589 2 0.457ICU admission (n) 8 6
Tracheal intubation (n) 4 3
NIV: non-invasive ventilation; ICU: intensive care unit.
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in public was not yet implemented in Malta. The enforce-
ment of mandatory wearing of masks in enclosed public
spaces began on the 3rd May 2020 [13]. During this time,
people above the age of 65 years and those immunocompro-
mised were encouraged to isolate and to work from home. As
of Saturday 17th October 2020, it became mandatory to wear
a face mask in indoor and outdoor spaces [14].
It is a well-known fact that pollution contributes heavily
to COPD exacerbations, morbidity, and mortality [15]. A
study exploring the air quality of the major capital cities
worldwide confirmed that with the lockdown measures
imposed during the COVID-19 pandemic, there was a reduc-
tion in the concentration of PM2.5 (particulate matter less
than 2.5 micrometers in diameter) and an improvement in
the overall air quality, providing a potential factor for the
reduced COPD admissions rate [16]. A study conducted in
Bergamo presented evidence that particulate matter may
increase transmission of COVID-19. These results may
explain why areas having high levels of air pollution also have
a higher COVID-19 case concentration [17]. In contrast to
expectations, PM2.5 in Malta did not show any reductions
following the implementation of COVID-19 measures,
unlike nitrogen dioxide (NO2), as a major source of PM2.5
is dust from the Sahara Desert [18].
There are various conflicting guidelines regarding
whether nebulised treatment is appropriate during the
COVID-19 pandemic. NICE and the British Thoracic Society
(BTS) recognise that unlike NIV, nebulised medication may
not be a viral AGP and does not pose a significant risk for
infection with COVID-19 [19, 20]. Contrary, the Global Ini-
tiative for Asthma (GINA) advises against nebulised medica-
tion use, advocating for the use of pressurised meter dose
inhalers (pMDIs) [21].
Between patient groups, a significant decrease in the use
of nebulised treatment was noted, as well as a reduction in
the administration of controlled oxygen via the venturi mask
was noted. This could be explained by fear of hypoxaemia in
admitted patients suspected of having the SARS-CoV-2 viral
infection. As mentioned above, guidelines concerning the use
of nebulised treatment differ widely between academic bod-
ies. NICE advises that as the aerosol from nebulised medica-
tion is derived from a non-patient source, it therefore does
not carry patient-derived particles and does not carry risk
for transmission of COVID-19. There was a shift from con-
trolled oxygen administration to normal face mask and
non-rebreather mask supplemental oxygen when comparing
2019 to 2020. This was due to infection control measures
implemented at the hospital during the study period limiting
the use of venturi masks. Somogyi et al. (2004) demonstrated
that venturi oxygen masks can produce a flow of potentially
infectious exhaled air during patient expiration [22]. Accord-
ing to Hui et al. (2014), the maximum distances of exhaled air
during the application of venturi masks and non-rebreather
masks are 0.4m and <0.1m, respectively [23]. Following
the study period, hospital policies regarding treatment algo-
rithms mentioned above were changed.
This study demonstrated a significant increase inmortality
for AECOPD patients admitted during the 2020 COVID-19
pandemic, even though none of these patients tested positive
for COVID-19. Based on our results, we hypothesised that
lack of controlled oxygen and nebulised treatment would be
the predictors towards explaining the difference in mortality.
On univariate analysis, thirteen predictors were found to
be significant predictors of mortality among all AECOPD
inpatient admissions. Among these variables, only differ-
ences in oxygen given upon admission and nebulised ther-
apy were significantly different between 2019 and 2020.
However, on logistic regression, these two variables did not
persist as predictors of mortality. Furthermore, from the pre-
dictors found to be significant (active malignancy, length of
stay, and SABA pre-admission treatment), none were found
to be significantly different between the two cohorts.
Several meta-analyses indicate that COPD patients are at
an increased risk of disease severity and mortality if they con-
tract COVID-19 [11, 24–28]. It is therefore recommended
that strict adherence to preventer medications is maintained
to limit the risk of exacerbations at such a time. The Cana-
dian Thoracic Society highlights this in their updated guide-
lines [24]. Kaye et al. (2020) found that this recommendation
resulted in a general increase in treatment adherence [29]. Of
note, during the initial phase of the pandemic, fewer patients
attended the outpatient department, resulting in fewer
COPD patients being seen by a respiratory specialist. This
may have led to poorer control of COPD and contributed
to the outcomes.
We cannot therefore explain the difference in mortality
found through the results of this study. These results may
indicate that the study was relatively underpowered, despite
all AECOPD admissions during the study period being
included.
6. Limitations
All data were collected from online medical records; there-
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Figure 3: Mortality in 2019 and 2020 during admission.
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were not reviewed as these are not available online. A dis-
charge summary was not available for cases where inpatient
death occurred, limiting the data available on severity of the
AECOPD and treatment received during the hospital stay.
Data collection was also limited by the accuracy and com-
pleteness of data documented in the discharge summary
and online medical records. This study did not evaluate any
difference in outpatient mortality in those suffering with
COPD, so no comment can be made on any increase in
out-of-hospital deaths due to the lack of presentation sug-
gested by the decrease in hospital admissions.
7. Conclusions
In conclusion, we noted a statistically significant decrease in
hospital admissions of patients with AECOPD during the
COVID-19 pandemic in 2020, when compared to 2019.
The year 2020 was proved to be a significant predictor for
inpatient mortality, with a significantly higher inpatient
mortality rate in 2020 compared to 2019. The decrease in
nebulised medication administered and controlled oxygen
treatment noted in the study period did not prove to be a sig-
nificant predictor of mortality when corrected for other var-
iables, and we cannot therefore explain with certainty the
difference in mortality found in this retrospective cohort
study.
Data Availability
No publicly archived datasets were generated. All available
data are included within the manuscript.
Table 6: Predictors of inpatient mortality identified by the logistic regression model.
Model fitting criteria Likelihood ratio tests
-2 log likelihood of reduced model Chi-square Df p value
Intercept 14.583 0.000 0
Year of admission 26.393 11.810 1 0.001
SABA pre-admission treatment 24.360 9.777 1 0.002
Active malignancy 23.580 8.997 1 0.003
Length of stay 18.558 3.975 1 0.046
SABA: short-acting beta-agonist.
Table 4: Continuous variables significantly related with inpatient mortality (analysed using independent samples t-test).
Mortality Sample size Mean Standard deviation p value
Patient age on admission (years)
Yes 45 76.71 8.064 <0.001
No 333 70.75 9.091
Total number of previous AECOPD admissions (n)
Yes 45 1.47 1.791 <0.001
No 328 4.67 6.644
Length of stay in hospital (days)
Yes 45 11.73 12.027
0.003
No 333 6.05 5.717
Days since last admission (days)
Yes 45 2.07 0.863
0.049
No 325 1.79 0.888
Table 5: Categorical variables that were significantly related with inpatient mortality (analysed using the chi-square test).
Death during admission Alive on discharge Chi-square p value
Year of admission (2019/2020, n) 22/23 237/96 9.125 0.003
Active malignancy (yes/no, n) 16/23 29/304 34.289 <0.001
Hypertension (yes/no, n) 35/6 201/132 9.803 0.002
Ischaemic heart disease (yes/no, n) 17/23 91/242 3.996 0.046
Oxygen given on admission (venturi/normal face mask/no oxygen, n) 2/5/1 175/18/24 25.228 <0.001
Nebuliser treatment (yes/no, n) 1/4 247/68 9.631 0.002
Admission to ICU (yes/no, n) 5/40 9/324 7.859 0.005
SABA pre-admission treatment (yes/no, n) 18/16 250/82 7.865 0.005
Diabetes (yes/no, n) 18/23 87/246 5.713 0.017
ICU: intensive care unit; SABA: short-acting beta-agonist.
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